Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SEOPAC: Liposomal irinotecan (Onivyde, 易安达) plus 5‑FU and leucovorin in metastatic pancreatic cancer after gemcitabine in China
CTR20243775Phase 4Active
- Sponsor
- Servier
- Start
- Dec 2024
- Modality
- Small Molecules, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
A Phase 4 trial of nanoliposomal irinotecan in pancreatic cancer (PC), sponsored by Servier. Started Dec 2024; status: active.
02
Drugs
nanoliposomal irinotecan
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on CTR20243775.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243775.